Shares of Rhythm Pharmaceuticals moved higher after the company reported preliminary six-month data from a Phase 2 study of setmelanotide in Prader-Willi syndrome, a rare genetic disorder marked by severe appetite drive and related metabolic complications. The results were presented at the Endocrine Society’s Annual Meeting (ENDO 2026) and the company said the strength of the data would support progression into a Phase 3 trial.
Rhythm Pharmaceuticals shares closed at $88.38 on Friday, up 0.82%. In pre-market trading, the stock was indicated higher at $90.86, up 2.81%.
Key takeaways
- Price move: Rhythm Pharmaceuticals shares rose in pre-market following the ENDO 2026 presentation.
- Catalyst: Preliminary six-month Phase 2 results for setmelanotide in Prader-Willi syndrome were presented at ENDO 2026.
- Body-weight signals: The company reported a mean BMI reduction and improvements in lean and fat mass measures.
- Behavioral outcomes: Hyperphagia questionnaire scores improved, alongside reductions in anxiety-related measures.
- Implication: Rhythm said the data supports advancing setmelanotide into a Phase 3 program for PWS.
What drove the move
Rhythm Pharmaceuticals reported preliminary outcomes from an ongoing Phase 2 trial evaluating setmelanotide, a melanocortin-4 receptor agonist approved for excess body weight and hypothalamic obesity, including U.S. approval in 2020. The company framed the six-month data as an important step toward a larger, confirmatory Phase 3 study in Prader-Willi syndrome.
The Phase 2 trial enrolled 18 patients with PWS and is designed with a 52-week treatment period. While the ENDO presentation covered the first six months of results, investors typically view such updates as a validation of both efficacy and potential tolerability signals early in development.
Six-month results in Prader-Willi syndrome
According to the company’s preliminary six-month data, pediatric and adult patients showed a 3.60% mean reduction in body-mass index (BMI). The report also cited a 0.35 mean reduction in BMI z-score from baseline, a metric used to contextualize changes relative to age- and sex-adjusted norms.
On body composition, Rhythm said patients on treatment demonstrated a 0.74 mean gain in lean mass and a 4.19 mean loss in fat mass, as measured by DEXA scans used to assess bone mineral density and related composition markers.
Beyond weight-related endpoints, the company highlighted changes in clinically relevant behavioral drivers of PWS. It reported that hyperphagia assessments based on a Hyperphagia Questionnaire for Clinical Trials (HQ-CT) showed a decrease of 7 or more points in moderate to severe hyperphagia among patients assessed.
Rhythm also said the treatment was associated with reduced anxiety in patients, based on results from the PWS Anxiousness and Distress Behaviors Questionnaire (PADQ).
Market reaction and what investors are likely watching
The stock’s upward move followed the company’s decision to publicly share interim efficacy signals across multiple domains—weight metrics, body composition, and patient-reported measures tied to appetite drive and anxiety. For investors, such a combination can be particularly important in rare diseases where endpoints often need to reflect both metabolic outcomes and day-to-day symptom burden.
Rhythm stated that the strength of the Phase 2 results would support moving into an upcoming Phase 3 trial for setmelanotide in Prader-Willi syndrome. That company guidance matters because Phase 3 execution is where efficacy must hold up more rigorously, often with clearer statistical targets and broader datasets.
Investors are likely to focus next on whether the improvements observed at six months persist through the full 52-week treatment period, including consistency across subgroups and the durability of changes in hyperphagia and anxiety. They may also track how the company will design endpoints and interpret the clinical significance of BMI-related measures in a population that includes both pediatric and adult patients.
Bigger picture for setmelanotide
Prader-Willi syndrome is a rare genetic disorder that leads to compulsive appetite and, for many patients, a pathway toward obesity and associated health complications. According to the report, there are an estimated 12,500 to 16,000 patients in the U.S. and Europe, with roughly 80% to 90% experiencing hyperphagia or obesity.
Setmelanotide’s existing approval for excess body weight and hypothalamic obesity provides a regulatory and commercial foundation, but the Phase 2 PWS readout is about expanding that profile into a distinct and high-need rare disease indication. The company’s ability to convert interim Phase 2 signals into a credible Phase 3 program could influence expectations for future growth, pipeline value, and the competitive landscape in obesity- and appetite-driven disorders.
For now, the key storyline is the company’s interim results at ENDO 2026 and its stated intent to advance to Phase 3. Investors will likely weigh the positive early data against the uncertainties that remain typical for early-stage updates, particularly regarding durability and the scale of effect when studied more broadly.
What to watch next: Rhythm is expected to continue reporting progress from the ongoing Phase 2 study as the 52-week treatment window approaches, and investors will look for details on the planned Phase 3 trial design and endpoints for setmelanotide in Prader-Willi syndrome. Additional market-moving updates could also come around broader biopharma and biotech sentiment, but the next direct catalysts are tied to the development program’s next milestones.
